Obi-wan
Member
- Joined
- Mar 16, 2017
- Messages
- 1,120
Interactions between mitochondrial reactive oxygen species and cellular glucose metabolism
Abstract
Mitochondrial reactive oxygen species (ROS) production and detoxification are tightly balanced. Shifting this balance enables ROS to activate intracellular signaling and/or induce cellular damage and cell death. Increased mitochondrial ROS production is observed in a number of pathological conditions characterized by mitochondrial dysfunction. One important hallmark of these diseases is enhanced glycolytic activity and low or impaired oxidative phosphorylation. This suggests that ROS is involved in glycolysis (dys)regulation and vice versa. Here we focus on the bidirectional link between ROS and the regulation of glucose metabolism. To this end, we provide a basic introduction into mitochondrial energy metabolism, ROS generation and redox homeostasis. Next, we discuss the interactions between cellular glucose metabolism and ROS. ROS-stimulated cellular glucose uptake can stimulate both ROS production and scavenging. When glucose-stimulated ROS production, leading to further glucose uptake, is not adequately counterbalanced by (glucose-stimulated) ROS scavenging systems, a toxic cycle is triggered, ultimately leading to cell death. Here we inventoried the various cellular regulatory mechanisms and negative feedback loops that prevent this cycle from occurring. It is concluded that more insight in these processes is required to understand why they are (un)able to prevent excessive ROS production during various pathological conditions in humans.
Summary and conclusion
ROS are produced as a consequence of normal mitochondrial energy metabolism. When transiently and/or moderately increased, ROS can activate signaling pathways involved in cellular adaptation to various types of (metabolic) stress. One of these pathways is the stimulation of glucose uptake. When ROS levels are too high and/or remain increased during a prolonged period of time, a vicious circle of ROS-stimulated glucose uptake and glucose-stimulated ROS production can be triggered. This pathological cycle can be broken by restoring mitochondrial ROS production to normal levels. We presented three major mechanisms that, in principle, can lower mitochondrial ROS production: (1) reducing glucose uptake, (2) increasing lactate secretion and (3) depolarization of Δψ. Unfortunately, these mechanisms have also been associated with increases in ROS and/or appear to be not effective in all experimental models. Undesirable side effects include reduced NADPH production during reduced glucose uptake, a high rate of lactate secretion potentially inducing lactic acidosis and induction of mitochondrial dysfunction and apoptosis by (high-magnitude) and/or prolonged Δψ depolarization. We conclude that cellular glucose metabolism and mitochondrial ROS production are coupled by various signaling mechanisms, which need to be controlled by the cell to avoid oxidative stress. A more detailed understanding of how these pathways interact with mitochondrial ROS production, endogenous antioxidant systems and mitochondrial/cellular function is required to explain why oxidative stress induction still appears to contribute to pathology induction in humans (e.g., diabetes, cancer, mitochondrial dysfunction).
Interactions between mitochondrial reactive oxygen species and cellular glucose metabolism
Great explanation @Mito on glucose generating ROS. Maybe even higher than beta oxidation. It also shows how complicated the process is. Also a higher metabolism will generate higher ROS (in my chart above) but then use a powerful antioxidant system to avoid oxidative stress The question is what came first, the pathology or the oxidative stress induction. Obvious answer is the pathology. The cells will use acute ROS to kill the pathology then temper the ROS with its antioxidant system. But why take external antioxidants to dampen the acute cycle then keep ROS steady state at a higher level as shown in the graph I posted above.
This was interesting " In general, if ROS levels exceed a certain threshold, they will impair OXPHOS complexes and further stimulate ROS production (Galloway and Yoon 2012). In the light of the above, it is not surprising that increased ROS levels, although not always oxidative stress, are observed during various pathological conditions. For example, primary fibroblasts derived either from CI deficient mice or patients show increased ROS levels, but no obvious signs of oxidative stress (Koopman et al. 2007; Valsecchi et al. 2013; Verkaart et al. 2007a, b). Increased ROS levels also have been observed in multiple types of cancer (e.g., prostate, colorectal, ovarian, pancreatic, breast, liver, bladder, melanoma, glioma), neurogenerative diseases (e.g., Alzheimer’s disease and Parkinson’s disease) and during insulin-resistance and diabetes"